Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
From MaRDI portal
Publication:5701106
DOI10.1093/biostatistics/2.2.203zbMath1097.62565OpenAlexW2110340629WikidataQ52010464 ScholiaQ52010464MaRDI QIDQ5701106
Publication date: 2 November 2005
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/2.2.203
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Related Items
Methodology and application of adaptive and sequential approaches in contemporary clinical trials ⋮ Number of patients per cohort and sample size considerations using dose escalation with overdose control ⋮ Dose finding with escalation with overdose control (EWOC) in cancer clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Cumulative cohort design for dose-finding ⋮ A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches ⋮ Simple benchmark for complex dose finding studies ⋮ Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials ⋮ A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents ⋮ A conversation with Nancy Flournoy